Tracing and targeting the epigenetic heterogeneity in breast cancer metastasis

追踪和靶向乳腺癌转移中的表观遗传异质性

基本信息

批准号：
10672517
负责人：
Igor Landry Bado
金额：
$ 24.9万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10672517
关键词：
3-Dimensional Address Advanced Malignant Neoplasm Advisory Committees Advocate Affect Anemia Bar Codes Bone Matrix Brain Breast Breast Cancer Cell Breast Cancer Model Breast cancer metastasis Calcium Calcium Signaling Cancer Etiology Career Mobility Cell Survival Cells Cessation of life Chromatin Clinical Management Clinical Trials Coculture Techniques Coma Complex Comprehensive Cancer Center DNA Sequence Alteration DNA methylation profiling Data EZH2 gene Endocrine Epigenetic Process Estrogen Receptors Estrogen receptor positive Estrogens Evolution FDA approved FGF2 gene FGFR1 gene Fibroblast Growth Factor Fostering Gap Junctions Genetic Genetic Heterogeneity Genetic Transcription Genomics Goals Growth Growth Factor Heterogeneity Hypercalcemia Incidence Individual Inherited Institution International Lesion Libraries Liver Lung Malignant Neoplasms Malignant neoplasm of brain Mediating Medicine Mentors Metastatic Neoplasm to the Bone Micrometastasis Molecular Mutation Neoplasm Metastasis Numbness Oncologist Organ Osteoblasts Osteoclasts Pain Paralysed Pathological fracture Patients Perfusion Phase Phenotype Platelet-Derived Growth Factor Positioning Attribute Process Proteomics Receptor Protein-Tyrosine Kinases Recurrence Research Resistance Resources Scientist Seeds Senior Scientist Signal Pathway Signal Transduction Site Spatial Distribution System TRANCE protein Techniques Technology Testing Therapeutic Tissue Microarray Transforming Growth Factor beta Transitional Epithelium Validation Variant XCL1 gene anticancer research base bone cancer cell cancer diagnosis cancer subtypes clinically relevant college conventional therapy epigenetic drug epigenomics epithelial to mesenchymal transition exome sequencing in vivo evaluation inflammatory breast cancer laser capture microdissection malignant breast neoplasm mammary gland development multiple omics non-genomic novel novel therapeutic intervention osteoblast differentiation overexpression parathyroid hormone-related protein professor public health relevance receptor expression single cell analysis single-cell RNA sequencing stemness therapy resistant trait transcriptomics treatment response tumor tumor growth tumor heterogeneity tumor progression

项目摘要

Project Summary Title: Tracing and targeting the epigenetic heterogeneity in breast cancer metastasis. Metastasis is major cause of cancer-related death and is the most challenging to treat. Besides the well-studied genomic mutations in cancer, our understanding of non-genomic alterations remains limited. The proposed approach is to dissect the mechanisms of non-genomic intra-metastasis heterogeneity in breast cancer. Recently, we demonstrated that osteoblasts (bone forming cells) promote a global alteration of chromatin organization which associates with increased stemness, epithelial to mesenchymal transition, and overexpression of multiple receptor tyrosine kinases included FGFR1 and PDGFRβ. Ultimately, estrogen signaling was inhibited while endocrine resistance was increased. Mechanistically, we identified FGF2/PDBFβ/ EZH2 axis as a novel regulator of epigenetic reprogramming in breast cancer bone metastasis. However, several outstanding questions remained unanswered: (i) what mechanisms drive phenotypic variations between neighboring cells in bone metastasis, (ii) are epigenetic traits inheritable during metastasis progression, and (ii) if yes, how do they influence therapeutic response? In this project, our goal is to understand the mechanisms of intra-tumor heterogeneity in bone metastases and determine how epigenetic heterogeneity affects therapeutic response beyond the genetic heterogeneity that has been extensively studied. We aim to trace and dissect the epigenetic intra-tumor heterogeneity (eITH) using a cutting-edge barcoding strategy (K99 phase), identify epigenetic modulators by integrating single cell multi-omics (K99-R00 phase), test new therapeutic approaches and eventually expand our findings to other breast cancer metastasis sites (R00 phase) including lung, liver, and brain. Baylor College of Medicine (BCM) is an internationally renowned institution for breast cancer research, which gives me the opportunity to closely interact, exchange ideas, and share my findings with leading scientists, clinicians and patient advocates. For my career transition, I assembled a team of senior scientists and experts including my mentor, Professor Xiang H-F Zhang, who is well-established in breast cancer bone metastasis. My co-mentor, Professor Jeffrey Rosen, is a distinguished scientist in mammary gland development and breast cancer modeling. Because of the clinical relevance of the project, I also included Professor C. Kent Osborne, founding director of the Dan L. Duncan Comprehensive Cancer Center (DLDCCC), Professor Matthew J. Ellis, a world-renowned oncologist and director of the Breast Center, Dr. Bora Lim, an expert in aggressive subtypes of breast cancer (e.g. inflammatory breast cancer), Professor Susan G. Hilsenbeck, a distinguished biostatistician, and Dr. Zhandong Liu a computational biologist and statistician with expertise in single cell analysis. Adding the expertise of my advisory team to the rich intellectual resource and cutting-edge technology available at BCM will facilitate my successful transition into an independent position at a top research institution.

项目摘要标题：追踪和靶向乳腺癌转移中表观遗传异质性。转移是造成癌症相关死亡的主要原因，是治疗的最挑战。除了经过深思熟虑之外癌症中的基因组突变，我们对非基因组改变的理解仍然有限。提议方法是剖析乳腺癌中非基因组内异质性的机制。最近，我们证明成骨细胞（骨形成细胞）促进了染色质的全局变化与茎的增加，上皮与间充质转变相关的组织，多种受体酪氨酸激酶的过表达包括FGFR1和PDGFRβ。最终，雌激素信号传导被抑制，而内分泌耐药性增加。从机械上讲，我们确定了FGF2/PDBFβ/ EZH2轴是乳腺癌骨转移中表观遗传重编程的新型调节剂。但是，有几个未解决的杰出问题尚未解决：（i）哪些机制驱动表型变化骨转移中的相邻细胞（II）是转移过程中可遗传的表观遗传特征，（ii）如果是，它们如何影响理论反应？在这个项目中，我们的目标是了解骨转移中肿瘤内异质性，并确定表观遗传异质性如何影响治疗超出已广泛研究的遗传异质性的反应。我们旨在追踪和剖析使用尖端的条形码策略（K99相），表观遗传性肿瘤内异质性（EITH），识别表观遗传调节剂通过整合单细胞多词（K99-R00期），测试新的治疗方法最终将我们的发现扩展到其他乳腺癌转移部位（R00期），包括肺，肝脏和脑。贝勒医学院（BCM）是一家国际知名的乳腺癌研究机构，这使我有机会与领先的科学家进行紧密互动，交换思想和分享我的发现，临床医生和患者拥护者。在我的职业过渡中，我组建了一支由高级科学家和专家组成的团队包括我的心理，Xiang H-f教授张教授，他在乳腺癌骨转移方面成熟。我的杰弗里·罗森（Jeffrey Rosen）教授是乳腺发育和乳房的杰出科学家癌症建模。由于该项目的临床意义，我还包括C. Kent Osborne教授， Dan L. Duncan综合癌症中心（DLDCCC）的创始董事Matthew J. Ellis教授一位世界知名的肿瘤学家兼乳房中心主任Bora Lim博士，攻击性子类型的专家Bora Lim博士乳腺癌（例如炎症性乳腺癌），苏珊·希尔森贝克（Susan G. Hilsenbeck）教授生物统计学家和Zhandong Liu博士是一位计算生物学家和统计学家，在单细胞中具有专业知识分析。将我的咨询团队的专业知识添加到丰富的知识分子和尖端技术中在BCM上可用，将促进我成功地过渡到顶级研究机构的独立职位。